InvestorsHub Logo
Followers 1
Posts 207
Boards Moderated 0
Alias Born 08/30/2018

Re: Johny Canuck post# 389

Thursday, 04/11/2019 4:51:29 PM

Thursday, April 11, 2019 4:51:29 PM

Post# of 2470
This is what I found..

https://www.linkedin.com/in/karin-studer-37276719/?originalSubdomain=ca

https://www.zoominfo.com/p/Ranj-Deol/-1866226807


http://www.otcmarkets.com/financialReportViewer?symbol=SRUTF&id=209675
Related Party Transactions and Balances
(a) Compensation of key management personnel
Key management personnel include those persons having authority and responsibility for planning,
directing and controlling the activities of the Company as a whole. The Company has determined that
key management personnel consist of members of the Company’s Board of Directors and corporate
officers.
The remuneration of key management personnel during the quarter ended was as follows:
Three months ended Six months ended
2018 2017 2018 2017
$ $ $ $
Management compensation (i) 196,072 174,449 385,899 244,532
Share-based compensation (ii) 317,843 87,434 477,018 151,107
513,915 261,883 862,917 395,639
(i) As of August 31, 2018, the Company owes $83,115 to key management personnel.
(ii) Share-based payments are the fair value of options granted and vested to key management
personnel and directors of the Company under the Company’s stock option plan.
(b) Loans from related parties
The Company has received loans from Bray Limited Partnership (Shareholder), 1023409 B.C. Ltd.
(Shareholder) and on demand loan related to a Director of the Company.
August 31, 2018 February 28, 2018
$ $
On-demand loan – Director - 100,000
Loan payable – 1023409 B.C. Ltd. 46,156 49,000
Due to related parties – Bray Limited Partnership - 1,581,887
46,156 1,730,887
(c) Due to related party
The Company has an outstanding cash consideration payment of $4,479,759 as part of the acquisition
of Infusion Biosciences Canada. The balance was settled upon the closing special warrant bought deal
financing.